C

CureVac NV
D

CVAC

2.74000
USD
-0.03
(-1.08%)
Market Closed
Volume
13,169
EPS
1
Div Yield
-
P/E
6
Market Cap
614,686,824
OverviewSignalsIdeasNews
Related Instruments
    AZN
    AZN
    -1.830
    (-2.81%)
    66.360 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    D
    DVAX
    -1.180
    (-8.81%)
    12.210 USD
    GILD
    GILD
    -3.715
    (-4.03%)
    88.385 USD
    I
    INO
    -0.54000
    (-11.25%)
    4.26000 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    154.520 USD
    MRNA
    MRNA
    -2.950
    (-7.42%)
    36.830 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.760 USD
    T
    TBIO
    0
    (0%)
    0.000000 USD
    V
    VXRT
    -0.05030
    (-7.97%)
    0.58050 USD
    More
News

Title: CureVac NV

Sector: Healthcare
Industry: Biotechnology
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.